Bordetella pertussis Infections is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Bordetella pertussis Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Bordetella pertussis Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bordetella pertussis Infections overview
Bordetella pertussis is a bacterium that causes pertussis, also known as whooping cough, a highly contagious respiratory infection. It spreads through droplets produced by coughing or sneezing, or by contact with contaminated surfaces or infected persons. Pertussis can cause severe complications and death, especially in infants who are not fully vaccinated. The symptoms of pertussis include runny nose, fever, cough, and a characteristic whooping sound when breathing in. The diagnosis of pertussis is based on symptoms, throat or nose culture, blood test, and chest X-ray. The treatment of pertussis involves antibiotics and supportive care. The prevention of pertussis is mainly achieved by vaccination and avoiding contact with infected persons.
For a complete picture of PTSR and LoA scores for drugs in Bordetella pertussis Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
